ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
NuitsSonores
|
17K |
6.8M |
30 |
02/04/21 |
02/04/21 |
ASX - By Stock
|
17K
|
6.8M
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Regenerative Medicine and Cell Therapies Virtual Event
|
|
NuitsSonores
|
129 |
57K |
37 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
129
|
57K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial
|
|
NuitsSonores
|
299 |
139K |
82 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
299
|
139K
|
82
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial
|
|
NuitsSonores
|
299 |
139K |
28 |
04/09/20 |
04/09/20 |
ASX - By Stock
|
299
|
139K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
NuitsSonores
|
576 |
234K |
24 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
576
|
234K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
NuitsSonores
|
576 |
234K |
11 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
576
|
234K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
NuitsSonores
|
576 |
234K |
112 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
576
|
234K
|
112
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
NuitsSonores
|
320 |
130K |
142 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
130K
|
142
|
|
ASX - By Stock
|
MSB |
Re:
(NON-TRADING) COVID-19 ARDS DISCUSSION
|
|
NuitsSonores
|
19 |
10K |
156 |
19/08/20 |
19/08/20 |
ASX - By Stock
|
19
|
10K
|
156
|
|
ASX - By Stock
|
MSB |
Re:
COVID ARDS interim analysis
|
|
NuitsSonores
|
37 |
20K |
44 |
09/08/20 |
09/08/20 |
ASX - By Stock
|
37
|
20K
|
44
|
|